Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05VIL
|
||||
| Former ID |
DAP001407
|
||||
| Drug Name |
Nalmefene
|
||||
| Synonyms |
Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Opioid addication [ICD10:F11] | Approved | [551871] | ||
| Therapeutic Class |
Anticraving Agents
|
||||
| Company |
Eurohealth International Sarl
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H25NO3
|
||||
| InChI |
InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
|
||||
| InChIKey |
WJBLNOPPDWQMCH-MBPVOVBZSA-N
|
||||
| CAS Number |
CAS 55096-26-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10227, 855608, 11039366, 12013834, 14753624, 14875634, 24897753, 39317900, 47206836, 48259434, 48416306, 49992724, 50103951, 51025118, 57359131, 103256810, 103976649, 124800059, 126686477, 129588878, 134221999, 134338615, 135004339, 135650681, 137244646, 139813941, 144204424, 162173089, 162225811, 164230833, 164779663, 164830448, 170465281, 175267830, 179150613, 184585438, 223440476, 223673675, 223880913, 226421524, 241096138
|
||||
| SuperDrug ATC ID |
N07BB05
|
||||
| Target and Pathway | |||||
| Target(s) | Opioid receptor | Target Info | Antagonist | [536742], [536928] | |
| References | |||||
| Ref 536742 | Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008 Jul;32(7):1159-66. | ||||
| Ref 536928 | Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. Epub 2008 Nov 10. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.